Related Experiment Videos
Proteomics: applications and opportunities in preclinical drug development
1Large Scale Proteomics Corporation, Rockville, MD 20850, USA. sandra.steiner@lsbc.com
Electrophoresis
|July 13, 2000
Summary
High-throughput proteomics, fueled by DNA sequencing advances, will transform pharmaceutical development. This will enable earlier clinical trials and more efficient drug efficacy and safety assessments using biological markers.
Area of Science:
- Biochemistry
- Genomics
- Drug Development
Background:
- Advances in DNA sequencing are enabling comprehensive genomic data acquisition.
- Proteomics offers significant potential for pharmaceutical research and development.
- Existing literature highlights the value of proteomics in preclinical drug studies.
Purpose of the Study:
- To explore the impact of genomic and proteomic advancements on pharmaceutical development.
- To outline the anticipated benefits of functional genomics and proteomics in drug discovery.
Main Methods:
- Leveraging public domain literature.
- Analyzing the potential of high-throughput proteomic studies.
- Forecasting the integration of genomics and proteomics in drug development.
Main Results:
- Whole genome sequences for key organisms will become readily available.
- Proteomics is poised to significantly influence preclinical pharmaceutical development.
- Functional genomics and proteomics are expected to impact clinical trial phases.
Conclusions:
- Genomic and proteomic data will enhance early proof-of-concept studies in humans.
- Biologically relevant markers derived from proteomics will improve clinical trial efficiency for drug efficacy and safety.